Kubota Yuta, Tanaka Kazuhiro, Hisaoka Masanori, Daa Tsutomu, Iwasaki Tatsuya, Kawano Masanori, Itonaga Ichiro, Tsumura Hiroshi
Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka Hasama, 879-5593, Yufu City, Oita, Japan.
Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, 807-8555, Kitakyushu, Japan.
BMC Musculoskelet Disord. 2021 Jan 21;22(1):99. doi: 10.1186/s12891-021-03969-4.
It is very rare for clear cell sarcomas (CCS) to arise in the bone. During diagnosis, it is important to distinguish primary CCS of bone from bone metastasis of melanoma because this difference fundamentally changes the therapeutic options. Recently, characteristic fusion genes of CCS have been detected using reverse transcription polymerase chain reaction (RT-PCR) or direct sequencing which allowed to distinguish CCS from melanoma. However, there was no study applying these analyses with positive results. In this case, we describe the use of fusion gene analysis to diagnose a primary CCS of the bone.
A 36-year-old male presented with a four-months history of left knee pain. Magnetic resonance imaging showed a lesion in the left femoral medial epicondyle. Histological examination of the biopsy specimen revealed proliferating oval or rounded cells. These cells had clear cytoplasm arranged in fascicles or compact nests with frequent deposits of brown pigment. Furthermore, immunohistochemistry analysis revealed that tumor cells were positive for S-100 protein, HMB-45, Melan-A, and SOX10. It stained negative for CD34 and BRAF v600e. Conclusively, detection of the EWSR1/ATF1 fusion gene using RT-PCR and direct sequencing confirmed that the lesion was a primary CCS of the bone. Wide-margin resection and reconstruction with a tumor endoprosthesis were performed.
Herein, we diagnosed a rare case of primary CCS of the bone by detecting EWSR1/ATF1 fusion gene using RT-PCR and direct sequencing. Since fluorescence-in situ hybridization (FISH) and RT-PCR could show false positive by mainly due to technical problems, it is better to perform direct sequencing to confidently diagnose the tumor as a primary CCS especially at very rare site such as bone.
透明细胞肉瘤(CCS)发生于骨内极为罕见。在诊断过程中,区分原发性骨CCS与黑色素瘤骨转移至关重要,因为这一差异会从根本上改变治疗方案。近来,通过逆转录聚合酶链反应(RT-PCR)或直接测序检测到了CCS的特征性融合基因,从而能够将CCS与黑色素瘤区分开来。然而,尚无应用这些分析方法获得阳性结果的研究报道。在此病例中,我们描述了如何利用融合基因分析诊断原发性骨CCS。
一名36岁男性,有4个月左膝疼痛病史。磁共振成像显示左股骨内侧髁有一病变。活检标本的组织学检查显示有增生的椭圆形或圆形细胞。这些细胞胞质透明,呈束状或紧密巢状排列,常有褐色色素沉积。此外,免疫组化分析显示肿瘤细胞S-100蛋白、HMB-45、Melan-A和SOX10呈阳性。CD34和BRAF v600e染色为阴性。最终,通过RT-PCR和直接测序检测到EWSR1/ATF1融合基因,证实该病变为原发性骨CCS。遂行广泛边缘切除并采用肿瘤人工关节假体进行重建。
在此,我们通过RT-PCR和直接测序检测EWSR1/ATF1融合基因,诊断了一例罕见的原发性骨CCS。由于荧光原位杂交(FISH)和RT-PCR主要因技术问题可能出现假阳性,对于将肿瘤确诊为原发性CCS,尤其是在骨这样非常罕见的部位,最好进行直接测序。